Clinical trials: Disorder, Mood
Affective Disorders
Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
The purpose of this study is to compare ziprasidone (Geodon) monotherapy for the treatment of psychotic major depression (PMD)with an antidepressant/antipsychotic combined therapy.
- Trial name
- NCT00340379
- Testing
- Ziprasidone, Sertraline, Haloperidol
- Where
- 3 sites in United States, Egypt and 1 more
- Volunteers
- 72 people
- Sponsor
- Duke University
Epilepsy, Psychiatric or Mood Diseases or Conditions
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Women who take folate (folic acid) before getting pregnant can lower the risk of giving birth to infant with certain birth defects. However, some medications may affect the action of folate.
- Trial name
- NCT01231646
- Testing
- No intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwell Health
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Major Depressive Disorder
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- NCT01473394
- Testing
- Vilazodone
- Where
- 14 sites in United States
- Volunteers
- 518 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy…
- Trial name
- NCT02951988
- Testing
- Rapastinel
- Where
- 137 sites in United States
- Volunteers
- 1,304 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
- Trial name
- VLZ-MD-23 (NCT02436239)
- Testing
- Vilazodone
- Where
- 56 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.
- Trial name
- NCT00422162
- Testing
- Duloxetine hydrochloride
- Where
- 35 sites in France, Italy and 2 more
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT04985942
- Testing
- Lumateperone
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 485 people
- Sponsor
- Intra-Cellular Therapies, Inc.
MDD
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
The MOOD study will evaluate the safety and efficacy of a noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP).
- Trial name
- MDD (NCT04279522)
- Testing
- Relivion®DP- Active
- Where
- 13 sites in United States, Israel
- Volunteers
- 124 people
- Sponsor
- Neurolief Ltd.
Psychotic Disorders, Depressive Disorder, Major
Treatment of Schizoaffective Disorder Using Mifepristone
This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
- Conditions
- Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
- Trial name
- NCT00725270
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Depression
Emotional and Cognitive Control in Late-Onset Depression
This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.
- Trial name
- NCT01728194
- Testing
- Escitalopram, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an…
- Trial name
- NCT03227224
- Testing
- JNJ-42847922
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 287 people
- Sponsor
- Janssen Research & Development, LLC
Stress Disorders, Post-Traumatic, PTSD
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
- Conditions
- Stress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
- Trial name
- KetPTSD (NCT00749203)
- Testing
- Midazolam, Ketamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Dennis Charney
Major Depressive Disorder, Treatment Resistant
Nuedexta in Treatment-Resistant Major Depression
There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD.
- Trial name
- NCT01882829
- Testing
- dextromethorphan/quinidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Major Depressive Disorder
Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature
The purpose of this study is to evaluate the comfort of the NeuroStar® Advanced Therapy System regular prescribed TMS protocol versus a New Feature.
- Trial name
- Comfort Start (NCT05535062)
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Neuronetics
Major Depressive Disorder
Study of Neural Responses Induced by Antidepressant Effects
The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
- Trial name
- SONRISA (NCT02674529)
- Testing
- Escitalopram, Real-time Neurofeedback fMRI task pre- and post-RCT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marta Peciña, MD PhD
Major Depressive Disorder
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved…
- Trial name
- STEP-D222 (NCT01052077)
- Testing
- OPC-34712, ADT
- Where
- 43 sites in United States
- Volunteers
- 773 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Reward Function and Therapy for Late-Life Depression
The goal of this study is to learn about changes in the brain that occur during Engage, a psychotherapy for depression in older adults, and how they may differ from changes that occur during supportive therapy.
- Trial name
- NCT03688139
- Testing
- Engage Therapy, Supportive Therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Weill Medical College of Cornell University
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03738215
- Testing
- Cariprazine
- Where
- 125 sites in United States, Bulgaria and 5 more
- Volunteers
- 759 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.